Tumor Tissue Microarrays for Cancer Research

High-Throughput Screening of FFPE Tumor Samples for Biomarker Discovery & Translational Oncology

Crown Bioscience’s Tissue Microarray (TMA) platform delivers a high-throughput, scalable solution for biomarker screening, discovery, and validation in oncology research. Designed for both preclinical and clinical applications, our TMAs are constructed from formalin-fixed, paraffin-embedded (FFPE) tumor tissue sourced from a comprehensive collection of murine models and a curated bank of human cancer specimens.

Our TMA portfolio includes arrays derived from:

• HuPrime® Patient-Derived Xenograft (PDX) models,

• Cell Line-Derived Xenograft models,

• Syngeneic models, and

• Murine tumor homograft (MuPrime™) models.

Each TMA features two to three representative cores per model and covers diverse tumor indications. PDX TMAs span cancer types such as colorectal, gastric, lung, liver, melanoma, pancreatic, sarcoma, and more. Cell Line-Derived TMAs provide mixed tumor types for broader screening, while syngeneic and MuPrime™ TMAs offer immunocompetent and murine homograft tumor models for immuno-oncology research.

Human TMAs for Translational Research

Our human tissue microarrays are ethically sourced and clinically annotated, enabling direct application to translational studies. These FFPE human TMAs span multiple cancer indications and support:

• Clinical biomarker validation

• Patient stratification strategies

• Human-relevant translational research

By integrating human TMAs with our robust preclinical model portfolio, researchers can bridge the gap between discovery and clinical development with greater confidence and efficiency.